<DOC>
	<DOCNO>NCT01097421</DOCNO>
	<brief_summary>This open-label , prospective post marketing surveillance study perform Sweden . Only data patient idiopathic PD document , treat physician plan initiate pharmacotherapy PPX ER independent observational study . The questionnaire ( Morisky Medication Adherence Measure , patient preference scale , CGI-I , PGI-I ) use document routine care standardized way thus ensure high validity observational data . As degree medication adherence patient routinely evaluated physician , patient preference possible symptom improvement initiation new therapy , patient questionnaire use standardise medical routine care ensure validity observational data .</brief_summary>
	<brief_title>Influence Pramipexole Extended Release Medication Adherence Parkinson´s Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients suffer idiopathic PD inclusion observation plan treat PPX ER accord SP , decision treatment make independently patients¿ inclusion observational study 2 . Stable dose PPX IR least 4 week inclusion observation 3 . Male female PD patient age least 30 4 . Ability reliably complete selfrating scale ( Morisky Medication Adherence Measure , patient preference scale ) accord physician¿s judgement 5 . Written informed consent patient study participation . Exclusion criterion : 1 . Patients able understand questionnaire ( e.g . due mental impairment language problem ) accord physician¿s judgement . 2 . Any contraindication PPX ER accord Summary Product Characteristics ( SPC ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>